ZyVersa Therapeutics Inc. (ZVSA) — Cash Flow-to-Debt Ratio
Latest as of September 2025:
-110.21x
ZyVersa Therapeutics Inc. (ZVSA) has a Cash Flow-to-Debt Ratio of -110.21x as of September 2025, meaning its operating cash flow of $-1.41 Billion could theoretically repay -110% of its total liabilities ($12.77 Million) in one year. See ZyVersa Therapeutics Inc. leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-110.21x
Operating CF / Total Liabilities
Operating Cash Flow
$-1.41 Billion
USD
Total Liabilities
$12.77 Million
USD
Data as of
Sep 2025
Most recent filing
ZyVersa Therapeutics Inc. Cash Flow-to-Debt Ratio (2020–2024)
Historical debt coverage capacity for ZyVersa Therapeutics Inc. across 5 annual periods. For the full cash flow conversion analysis, see ZyVersa Therapeutics Inc. operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for ZyVersa Therapeutics Inc. (2020–2024)
Year-by-year debt coverage analysis for ZyVersa Therapeutics Inc..
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.63x | $-7.56 Million | $12.08 Million | ▲ +20.8% |
| 2023 | -0.79x | $-8.72 Million | $11.04 Million | ▼ -199.1% |
| 2022 | -0.26x | $-4.89 Million | $18.51 Million | ▲ +29.1% |
| 2021 | -0.37x | $-5.08 Million | $13.63 Million | ▲ +32.6% |
| 2020 | -0.55x | $-5.11 Million | $9.24 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.